Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16219465rdf:typepubmed:Citationlld:pubmed
pubmed-article:16219465lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C0003289lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C0268563lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C1415803lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:16219465lifeskim:mentionsumls-concept:C2936518lld:lifeskim
pubmed-article:16219465pubmed:issue24lld:pubmed
pubmed-article:16219465pubmed:dateCreated2005-11-1lld:pubmed
pubmed-article:16219465pubmed:abstractTextNovel 5-HT(1) autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT(1A) and 5-HT(1B) receptors. Strategies for the development of dual 5-HT(1A) and 5-HT(1B) antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT(1A) and the 5-HT(1B) receptors and was characterized further with respect to selectivity, electrically stimulated [(3)H]5-HT release and in vivo efficacy.lld:pubmed
pubmed-article:16219465pubmed:languageenglld:pubmed
pubmed-article:16219465pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:citationSubsetIMlld:pubmed
pubmed-article:16219465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16219465pubmed:statusMEDLINElld:pubmed
pubmed-article:16219465pubmed:monthDeclld:pubmed
pubmed-article:16219465pubmed:issn0960-894Xlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:KlingAndreasAlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:HornbergerWil...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:LangeUdo E...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:MackHelmutHlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:SchmidtMartin...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:HutchinsCharl...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:MöllerAchimAlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:DrescherKarla...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:UngerLilianeLlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:MüllerReinhol...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:BakkerMargot...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:WickeKarstenKlld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:SchellhaasKur...lld:pubmed
pubmed-article:16219465pubmed:authorpubmed-author:SteinerGerdGlld:pubmed
pubmed-article:16219465pubmed:issnTypePrintlld:pubmed
pubmed-article:16219465pubmed:day15lld:pubmed
pubmed-article:16219465pubmed:volume15lld:pubmed
pubmed-article:16219465pubmed:ownerNLMlld:pubmed
pubmed-article:16219465pubmed:authorsCompleteYlld:pubmed
pubmed-article:16219465pubmed:pagination5567-73lld:pubmed
pubmed-article:16219465pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:meshHeadingpubmed-meshheading:16219465...lld:pubmed
pubmed-article:16219465pubmed:year2005lld:pubmed
pubmed-article:16219465pubmed:articleTitleSynthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.lld:pubmed
pubmed-article:16219465pubmed:affiliationNeuroscience Discovery, Abbott GmbH & Co. KG, D-67008 Ludwigshafen, Germany. andreas.kling@abbott.comlld:pubmed
pubmed-article:16219465pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16219465lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16219465lld:pubmed